Pulmonary Aspergillosis in Immunocompromised Critically Ill Patients: Prevalence, Risk Factors, Clinical Features and Diagnosis—A Narrative Review
Authors:
- Maria Grazia BocciMaria Grazia Bocci
- Laura CascaranoLaura Cascarano
- Giulia CapecchiGiulia Capecchi
- Antonio LesciAntonio Lesci
- Valerio SabatiniValerio Sabatini
- Dorotea RubinoDorotea Rubino
- Giulia Valeria StaziGiulia Valeria Stazi
- Gabriele GarottoGabriele Garotto
- Stefania CarraraStefania Carrara
- Antonella VulcanoAntonella Vulcano
- Chiara GoriChiara Gori
- Franca Del NonnoFranca Del Nonno
Open Access
- 24 August 2025
- journal article
- review article
- Published by MDPI AG in Journal of Fungi
- Vol. 11 (9) , 617
Abstract
Aspergillosis in immunocompromised individuals is a serious and potentially life-threatening infection, as the weakened immune system cannot effectively fight the Aspergillus fungus. This review provides an in-depth examination of aspergillosis in patients with various conditions that compromise immunity, including hematological disorders, HIV, SARS-CoV-2 pneumonia, influenza, and those who have undergone solid organ transplants. The clinical manifestations of aspergillosis are influenced by factors such as the host’s underlying comorbidities, immune response, and immune suppression due to medications or treatments. The review delves into the epidemiology of aspergillosis, exploring various risk factors that predispose individuals to infection. It also discusses the wide range of clinical symptoms, highlighting the challenges in diagnosis and the importance of early detection. The review contrasts traditional diagnostic approaches with emerging molecular techniques, emphasizing the role of advanced diagnostics in improving outcomes. A proposed clinical decision-making flowchart is provided to assist healthcare professionals in managing suspected cases of aspergillosis. In addition to diagnostic challenges, the review addresses antifungal prophylaxis, pre-emptive therapy, and the growing concern of pharmacological resistance to antifungal agents. It concludes with a discussion of future research directions, underscoring the need for improved therapeutic strategies and preventative measures in immunocompromised patients to reduce the burden of this severe fungal infection.Keywords
This publication has 161 references indexed in Scilit:
- Invasive Fungal Diseases in Adult Patients in Intensive Care Unit (FUNDICU): 2024 consensus definitions from ESGCIP, EFISG, ESICM, ECMM, MSGERC, ISAC, and ISHAMIntensive Care Medicine, 2024
- Epidemiology and Prevalence of Azole-Resistant Aspergillus fumigatus: What Is Our Understanding of the Situation?Current Fungal Infection Reports, 2023
- A Comparison of Diagnostic Criteria for Invasive Pulmonary Aspergillosis in Critically Ill PatientsInfectious Diseases and Therapy, 2023
- Posaconazole for prevention of invasive pulmonary aspergillosis in critically ill influenza patients (POSA-FLU): a randomised, open-label, proof-of-concept trialIntensive Care Medicine, 2021
- Invasive pulmonary aspergillosis after liver transplantation: lessons from successfully treated cases and review of the literatureSurgery Today, 2021
- Review of influenza-associated pulmonary aspergillosis in ICU patients and proposal for a case definition: an expert opinionIntensive Care Medicine, 2020
- Influenza-associated aspergillosis in critically-ill patients—a retrospective bicentric cohort studyEuropean Journal of Clinical Microbiology & Infectious Diseases, 2020
- Trial of complete weaning from immunosuppression for liver transplant recipients: Factors predictive of toleranceLiver Transplantation, 2013
- The intensive care support of patients with malignancy: do everything that can be doneIntensive Care Medicine, 2005
- Chemotherapy‐induced neutropeniaCancer, 2004